Body Body News Body March 18, 2025Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Dr. Reddy's reaches important milestone as the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03 (denosumab)View Article Body February 6, 2025Henlius and Dr. Reddy’s Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the US Dr. Reddy’s will gain exclusive rights to commercialize subcutaneous and IV formulations across 42 European countries and regions and the United StatesView Article Body May 21, 2024Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the US, Europe and UK Dr. Reddy’s gets exclusive commercialization rights in the United States (US) as well as semi-exclusive rights in Europe and United Kingdom (UK)View Article Body December 6, 2023Coya Therapeutics, Inc. and Dr. Reddy's Laboratories enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) Under the Agreement, Dr. Reddy's will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALSView Article Body January 20, 2023Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the US, Europe Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union, and other regionsView Article
